Korea To Expand Drug Support Incentives, Ease Listing Requirements
This article was originally published in PharmAsia News
South Korea is seeking to nurture the health care industry by new means such as easing the requirements for bioventures to stay listed on the Kosdaq market, as well as through drug development incentives such as extended tax benefits. The plan is part of a broader government measures to prop up investments in industries.
Register for our free email digests: